Related Experiment Video
Updated: May 26, 2026

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
Published on: November 11, 2025
Current models and strategies in the development of antiobesity drugs
James S Kinsey-Jones1, Kevin G Murphy
1Section of Investigative Medicine, Department of Diabetes, Endocrinology and Metabolism, Hammersmith Campus, Imperial College London, London, United Kingdom.
Abstract:
Animal models have enabled investigation of the complex mechanisms underlying energy homeostasis and, therefore, the development of antiobesity drugs.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients
Obesity
Oral Hypoglycemic Agents: Biguanides and Glitazones

